Immunotherapy (IO) and tyrosine kinase inhibitor (TKI) are now listed in the NCCN guidelines for advanced non–clear cell renal cell carcinoma (nccRCC).1 This change comes based on the efficacy seen with lenvatinib (Lenvima) plus pembrolizumab…
NCCN Guidelines in nccRCC Weigh New Data for Combinations | Targeted Oncology
